

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C12Q 1/68, G01N 33/574</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/43548</b> <b>(43) International Publication Date:</b> 27 July 2000 (27.07.00)
<b>(21) International Application Number:</b> PCT/US00/01599 <b>(22) International Filing Date:</b> 21 January 2000 (21.01.00) <b>(30) Priority Data:</b> 60/116,551 21 January 1999 (21.01.99) US <b>(71) Applicant (for all designated States except US):</b> BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA [US/US]; Regents Hall, 3835 Holdrege Street, Lincoln, NE 68598 (US). <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> LIN, Ming-Fong [US/US]; 327 S. 92nd Street, Omaha, NE 68114 (US). <b>(74) Agents:</b> KLANN, Ellen, M. et al.; Dann, Dorfman, Herrell and Skillman, Suite 720, 1601 Market Street, Philadelphia, PA 19103 (US).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> THERAPEUTIC AND DIAGNOSTIC APPLICATIONS OF PROSTATIC ACID PHOSPHATASE IN PROSTATE CANCER <b>(57) Abstract</b> <p>Presented is a therapeutic method to treat prostate carcinomas in mammals comprising the administration of cellular PAcP protein. Also presented is a method to diagnose androgen-insensitive prostate carcinomas by determining the expression level of cellular PAcP in the prostate carcinomas, a decrease in expression being indicative of androgen-insensitivity. A promoter region that is specifically expressed in prostate tissue is presented, as is a xenograft animal model that mimics human prostate carcinomas in the expression of cellular PAcP.</p>		